U.S. v. Teva Pharmaceuticals USA Inc. and Glenmark Pharmaceuticals Inc., USA


Teva Pharmaceuticals USA Inc. was charged with participating in three conspiracies to suppress and eliminate competition by agreeing to fix prices, allocate customers, and rig bids for generic drugs. In the first count, Glenmark was charged along with Teva with knowingly entering into and engaging in a conspiracy to suppress and eliminate competition by agreeing to increase and maintain prices of pravastatin and other generic drugs sold in the United States. The charged conspiracies took place between 2013 and 2015.

For further information:

For questions about upcoming public hearings or victims’ rights, contact the Victim Hearing Coordinator in the Washington Criminal I Section.

Case Documents:

Stipulated Protective Order (September 29, 2020)

Second Superseding Indictment (August 25, 2020)

Case Open Date: 
Tuesday, August 25, 2020
Case Name: 
United States v. Teva Pharmaceuticals USA, Inc.
Case Type: 
Case Violation: 
Bid Rigging
Customer, Territorial or Market Allocation - Horizontal
Price Fixing - Horizontal
Generic Drugs
Industry Code: 
Pharmaceutical and Medicine Manufacturing
Antitrust Division
Updated October 14, 2020